Communiqués Mustang Bio, Inc.

Actions

MBIO

US62818Q2030

Temps réel estimé Cboe BZX Autres places de cotation 16:51:48 28/06/2024			Varia. 5j.	Varia. 1 janv.
0,492 ^USD	+5,67 %		-11,42 %	-63,56 %

21/06	Le secteur des soins de santé est stable avant le marché vendredi	MT
20/06	Mustang Bio va lever 2,5 millions de dollars par le biais d'une offre d'actions	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	20/06	AQ
Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of phase Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy	18/06	AQ
Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy	17/06	AQ
Mustang Bio Announces Closing of $4 Million Public Offering	02/05	AQ
Mustang Bio Announces Pricing of $4 Million Public Offering	30/04	AQ
Mustang Bio : Results of Operations and Financial Condition - Form 8-K	29/04	PU
Mustang Bio : Costs Associated with Exit/Disposal - Form 8-K	12/04	PU
Mustang Bio : Corporate Presentation	01/04	PU
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases	28/03	AQ
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights	11/03	AQ
City of Hope-developed chimeric antigen receptor T cell therapy shows clinical activity in patients with aggressive brain tumors in a Phase 1 trial	08/03	AQ
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma	07/03	AQ
Mustang Bio : Corporate Presentation	01/03	PU
Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference	11/01	AQ
Mustang Bio Presents Updated Phase Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology Annual Meeting	12/12	AQ
Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting	11/12	AQ
Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights	14/11	AQ
Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting	02/11	AQ
Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	30/10/23	AQ
Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 and MB-108, for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma	27/10/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Mustang Bio, Inc.

Actions

MBIO

US62818Q2030

Communiqués

Filtres